Otsuka, Shape ink potential $1.5B deal to develop eye AAV gene therapies R&D, Therapeutics To build its ophthalmology portfolio, Japan’s Otsuka Pharmaceuticals has teamed with RNA editing biotech Shape Therapeutics to develop adeno-associated virus gene therapies for ocular diseases. Read more September 8, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2023/09/virus-vector.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-09-08 09:02:012023-09-08 09:02:01Otsuka, Shape ink potential $1.5B deal to develop eye AAV gene therapies
